8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Feb 20, 2026·SEC
ICU Medical, Inc.(ICUI)Earnings, Financials & Key Ratios
ICUI•NASDAQ
4774.5× P/E·Price updated Jun 19, 2026
AboutICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.Show more
- Revenue$2.23B-6.4%
- EBITDA$325M+615.7%
- Net Income$732K+100.6%
- EPS (Diluted)0.03+100.6%
- Gross Margin36.76%+6.2%
- EBITDA Margin14.57%+664.5%
- Operating Margin4.8%+165.9%
- Net Margin0.03%+100.7%
- ROE0.04%+100.6%
ICUI Key Insights
ICU Medical, Inc. (ICUI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 11.9%
✗Weaknesses
- ✗Profits declining 61.5% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ICUI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ICUI Price & Volume
ICU Medical, Inc. (ICUI) stock price & volume — 10-year historical chart
Loading chart...
ICUI Growth Metrics
ICU Medical, Inc. (ICUI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years20.63%
5 Years11.9%
3 Years-0.74%
TTM-10.89%
Profit CAGR
10 Years-33.76%
5 Years-61.53%
3 Years-
TTM149.46%
EPS CAGR
10 Years-36.43%
5 Years-62.6%
3 Years-
TTM148.3%
Return on Capital
10 Years3.84%
5 Years2.15%
3 Years1.56%
Last Year2.97%
ICUI Recent Earnings
ICU Medical, Inc. (ICUI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.97+10.7%
$1.78
Rev
$526M+1.0%
$521M
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$1.91+13.7%
$1.68
Rev
$536M+1.0%
$531M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$2.03+42.0%
$1.43
Rev
$537M+5.0%
$511M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$2.10+45.8%
$1.44
Rev
$549M+7.3%
$511M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.97vs $1.78+10.7% | $526Mvs $521M+1.0% |
| Q1 2026 | Feb 19, 2026 | $1.91vs $1.68+13.7% | $536Mvs $531M+1.0% |
| Q4 2025 | Nov 6, 2025 | $2.03vs $1.43+42.0% | $537Mvs $511M+5.0% |
| Q3 2025 | Aug 7, 2025 | $2.10vs $1.44+45.8% | $549Mvs $511M+7.3% |
Based on last 12 quarters of dataView full earnings history →
ICUI Peer Comparison
ICU Medical, Inc. (ICUI) competitors in Drug delivery and infusion consumables — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BDX | 52.16B | 143.98 | 24.70 | 8.23% | 5.33% | 4.54% | 0.76 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 ITGR | 3.13B | 90.96 | 31.47 | 7.57% | 7.67% | 8.23% | 0.80 | |
 AVA | 3.29B | 39.76 | 16.71 | 1.34% | 10.75% | 7.65% | 1.25 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% |
Compare ICUI vs Peers
ICU Medical, Inc. (ICUI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ICUI Income Statement
ICU Medical, Inc. (ICUI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.29B | 1.4B | 1.27B | 1.27B | 1.32B | 2.28B | 2.26B | 2.38B | 2.23B | 2.16B |
Revenue Growth % | 240.72% | 8.31% | -9.56% | 0.38% | 3.56% | 73.21% | -0.92% | 5.44% | -6.38% | -10.89% |
Cost of Goods Sold | 866.52M | 830.01M | 794.34M | 809.51M | 824.82M | 1.58B | 1.52B | 1.56B | 1.41B | 1.37B |
COGS % of Revenue | 67.04% | 59.28% | 62.73% | 63.69% | 62.66% | 69.4% | 67.25% | 65.38% | 63.24% | - |
Gross Profit | 426.1M▲ 0% | 570.03M▲ 33.8% | 471.86M▼ 17.2% | 461.5M▼ 2.2% | 491.49M▲ 6.5% | 697.76M▲ 42.0% | 739.87M▲ 6.0% | 824.78M▲ 11.5% | 819.65M▼ 0.6% | 784.17M▲ 0% |
Gross Margin % | 32.96% | 40.72% | 37.27% | 36.31% | 37.34% | 30.6% | 32.75% | 34.62% | 36.76% | 36.36% |
Gross Profit Growth % | 111.57% | 33.78% | -17.22% | -2.2% | 6.5% | 41.97% | 6.04% | 11.48% | -0.62% | - |
Operating Expenses | 355.21M | 381.01M | 364.5M | 363.33M | 368.25M | 740.66M | 717.05M | 781.82M | 712.71M | 703.96M |
OpEx % of Revenue | 27.48% | 27.21% | 28.79% | 28.59% | 27.98% | 32.49% | 31.74% | 32.82% | 31.96% | - |
Selling, General & Admin | 303.95M | 328.15M | 276.98M | 283.95M | 302.58M | 608.35M | 606.69M | 638.76M | 625.21M | 622.54M |
SG&A % of Revenue | 23.51% | 23.44% | 21.87% | 22.34% | 22.99% | 26.68% | 26.86% | 26.82% | 28.04% | - |
Research & Development | 51.25M | 52.87M | 48.61M | 42.95M | 47.5M | 92.98M | 85.34M | 88.61M | 87.5M | 85.48M |
R&D % of Revenue | 3.97% | 3.78% | 3.84% | 3.38% | 3.61% | 4.08% | 3.78% | 3.72% | 3.92% | - |
Other Operating Expenses | -2.48M | 1.47M | 38.91M | 36.43M | 18.16M | 39.33M | 25.01M | 54.44M | 0 | 1000K |
Operating Income | -15.08M▲ 0% | 21.61M▲ 243.3% | 107.36M▲ 396.8% | 98.16M▼ 8.6% | 123.25M▲ 25.6% | -42.9M▼ 134.8% | 22.82M▲ 153.2% | 42.96M▲ 88.2% | 106.95M▲ 148.9% | 80.22M▲ 0% |
Operating Margin % | -1.17% | 1.54% | 8.48% | 7.72% | 9.36% | -1.88% | 1.01% | 1.8% | 4.8% | 3.72% |
Operating Income Growth % | -118.18% | 243.33% | 396.76% | -8.57% | 25.55% | -134.81% | 153.21% | 88.23% | 148.93% | - |
EBITDA | 51.49M | 96.35M | 184.28M | 193.01M | 222.54M | 192.25M | 251.6M | 45.4M | 324.94M | 285.05M |
EBITDA Margin % | 3.98% | 6.88% | 14.55% | 15.19% | 16.91% | 8.43% | 11.14% | 1.91% | 14.57% | 13.22% |
EBITDA Growth % | -49.51% | 87.11% | 91.26% | 4.74% | 15.3% | -13.61% | 30.87% | -81.96% | 615.75% | 1.85% |
D&A (Non-Cash Add-back) | 66.57M | 74.73M | 76.92M | 94.85M | 99.29M | 235.15M | 228.77M | 2.44M | 217.99M | 204.84M |
EBIT | 53.33M | 197.16M | 115.26M | 99.25M | 124.17M | -43.6M | 24.43M | 40.53M | 108.55M | 109.63M |
Net Interest Income | -2.05M | -709K | -549K | 1.92M | 1.98M | -66.38M | -95.22M | -95.75M | -95.07M | -46.56M |
Interest Income | 0 | 0 | 0 | 3.68M | 2.84M | 4.43M | 7.51M | 10.79M | 10.31M | 4.65M |
Interest Expense | 2.05M | 709K | 549K | 1.75M | 858K | 70.81M | 102.73M | 106.54M | 105.38M | 51.22M |
Other Income/Expense | 64.58M | -7.38M | 7.35M | -668K | -59K | -71.51M | -101.12M | -108.98M | -103.78M | -70.72M |
Pretax Income | 51.28M▲ 0% | 22.37M▼ 56.4% | 114.71M▲ 412.7% | 97.49M▼ 15.0% | 123.19M▲ 26.4% | -114.41M▼ 192.9% | -78.3M▲ 31.6% | -66.01M▲ 15.7% | 3.17M▲ 104.8% | 9.49M▲ 0% |
Pretax Margin % | 3.97% | 1.6% | 9.06% | 7.67% | 9.36% | -5.02% | -3.47% | -2.77% | 0.14% | 0.44% |
Income Tax | -17.36M | -6.42M | 13.67M | 10.62M | 20.05M | -40.12M | -48.64M | 51.68M | 2.44M | -36.85M |
Effective Tax Rate % | -33.85% | -28.69% | 11.92% | 10.9% | 16.28% | 35.07% | 62.13% | -78.28% | 76.9% | -388.15% |
Net Income | 68.64M▲ 0% | 28.79M▼ 58.1% | 101.03M▲ 250.9% | 86.87M▼ 14.0% | 103.14M▲ 18.7% | -74.29M▼ 172.0% | -29.66M▲ 60.1% | -117.69M▼ 296.9% | 732K▲ 100.6% | 46.34M▲ 0% |
Net Margin % | 5.31% | 2.06% | 7.98% | 6.83% | 7.84% | -3.26% | -1.31% | -4.94% | 0.03% | 2.15% |
Net Income Growth % | 8.81% | -58.05% | 250.9% | -14.02% | 18.72% | -172.03% | 60.08% | -296.86% | 100.62% | 149.46% |
Net Income (Continuing) | 68.64M | 28.79M | 101.03M | 86.87M | 103.14M | -74.29M | -29.66M | -117.69M | 732K | 46.34M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 3.29▲ 0% | 1.33▼ 59.6% | 4.69▲ 252.6% | 4.02▼ 14.3% | 4.74▲ 17.9% | -3.11▼ 165.6% | -1.23▲ 60.5% | -4.83▼ 292.7% | 0.03▲ 100.6% | 1.84▲ 0% |
EPS Growth % | -10.11% | -59.57% | 252.63% | -14.29% | 17.91% | -165.61% | 60.45% | -292.68% | 100.61% | 148.3% |
EPS (Basic) | 3.50 | 1.33 | 4.90 | 4.16 | 4.86 | -3.11 | -1.23 | -4.83 | 0.03 | - |
Diluted Shares Outstanding | 20.86M | 21.6M | 21.55M | 21.59M | 21.78M | 23.87M | 24.09M | 24.39M | 24.9M | 25.18M |
Basic Shares Outstanding | 19.61M | 21.6M | 20.63M | 20.91M | 21.21M | 23.87M | 24.09M | 24.39M | 24.64M | 24.76M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ICUI Balance Sheet
ICU Medical, Inc. (ICUI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 864.66M | 927.04M | 882.2M | 914.38M | 1.03B | 1.24B | 1.22B | 1.44B | 1.18B | 1.19B |
Cash & Short-Term Investments | 300.13M | 382.11M | 292.64M | 410.78M | 567.25M | 213.01M | 254.72M | 308.57M | 307.96M | 288.33M |
Cash Only | 290.07M | 344.78M | 268.67M | 396.1M | 552.83M | 208.78M | 254.22M | 308.57M | 307.96M | 288.33M |
Short-Term Investments | 10.06M | 37.33M | 23.97M | 14.69M | 14.42M | 4.22M | 501K | 0 | 0 | 0 |
Accounts Receivable | 149.12M | 196.44M | 202.22M | 127.77M | 124.81M | 246.9M | 182.15M | 202.7M | 180.51M | 201.08M |
Days Sales Outstanding | 42.11 | 51.21 | 58.29 | 36.69 | 34.61 | 39.53 | 29.43 | 31.06 | 29.55 | 34.61 |
Inventory | 288.66M | 311.16M | 337.64M | 314.93M | 290.24M | 696.01M | 709.36M | 584.68M | 615.86M | 605.59M |
Days Inventory Outstanding | 121.59 | 136.83 | 155.15 | 142 | 128.44 | 160.56 | 170.42 | 137.04 | 159.38 | 163.59 |
Other Current Assets | 38.89M | 21.1M | 27.16M | 25.24M | 20.27M | 43.05M | 41.01M | 321.42M | 47.63M | 69.75M |
Total Non-Current Assets | 632.29M | 658.36M | 810.18M | 849.32M | 850.93M | 3.28B | 3.16B | 2.76B | 2.86B | 2.82B |
Property, Plant & Equipment | 398.68M | 432.64M | 490.55M | 513.2M | 510.88M | 713.58M | 685.52M | 499.3M | 506.29M | 502.13M |
Fixed Asset Turnover | 3.24x | 3.24x | 2.58x | 2.48x | 2.58x | 3.20x | 3.30x | 4.77x | 4.40x | 4.24x |
Goodwill | 12.36M | 11.2M | 31.25M | 33M | 43.44M | 1.45B | 1.47B | 1.43B | 1.5B | 1.49B |
Intangible Assets | 143.75M | 133.42M | 211.41M | 197.23M | 188.31M | 982.77M | 870.59M | 740.79M | 633.56M | 598.97M |
Long-Term Investments | 14.58M | 2.02M | 0 | 12.97M | 7.86M | 3.69M | 3.12M | 8.76M | 131.59M | 528.97M |
Other Non-Current Assets | 38.14M | 40.42M | 48.98M | 61.88M | 57.83M | 99.69M | 88.19M | 56.11M | 62.88M | 80.79M |
Total Assets | 1.5B▲ 0% | 1.59B▲ 5.9% | 1.69B▲ 6.7% | 1.76B▲ 4.2% | 1.88B▲ 6.6% | 4.52B▲ 140.1% | 4.38B▼ 3.0% | 4.2B▼ 4.0% | 4.05B▼ 3.6% | 4.01B▲ 0% |
Asset Turnover | 0.86x | 0.88x | 0.75x | 0.72x | 0.70x | 0.50x | 0.52x | 0.57x | 0.55x | 0.53x |
Asset Growth % | 112.43% | 5.91% | 6.75% | 4.21% | 6.64% | 140.1% | -3.04% | -3.99% | -3.65% | -16.61% |
Total Current Liabilities | 210.29M | 249.29M | 248.47M | 195.49M | 200.78M | 494.56M | 481.84M | 556.18M | 498.86M | 517.9M |
Accounts Payable | 78.23M | 120.47M | 128.63M | 71.86M | 81.13M | 215.9M | 150.03M | 148.02M | 154.37M | 173.98M |
Days Payables Outstanding | 32.95 | 52.98 | 59.1 | 32.4 | 35.9 | 49.81 | 36.04 | 34.69 | 39.95 | 44.48 |
Short-Term Debt | 0 | 0 | 0 | 9.29M | 0 | 29.69M | 51M | 51M | 34.67M | 34.19M |
Deferred Revenue (Current) | 3.33M | 3.81M | 6.7M | 5.57M | 12.65M | 30.84M | 31.64M | 30.36M | 33.84M | 145.32M |
Other Current Liabilities | 67.31M | 58.61M | 15.22M | 53.51M | 33.11M | 42.93M | 71.21M | 103.17M | 134.25M | 134.86M |
Current Ratio | 4.11x | 3.72x | 3.55x | 4.68x | 5.13x | 2.50x | 2.53x | 2.59x | 2.36x | 2.30x |
Quick Ratio | 2.74x | 2.47x | 2.19x | 3.07x | 3.68x | 1.09x | 1.06x | 1.54x | 1.13x | 1.13x |
Cash Conversion Cycle | 130.75 | 135.07 | 154.33 | 146.29 | 127.14 | 150.28 | 163.81 | 133.4 | 148.98 | 153.73 |
Total Non-Current Liabilities | 88.41M | 72.45M | 66.67M | 65.94M | 63.93M | 1.93B | 1.77B | 1.68B | 1.43B | 1.38B |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 1.62B | 1.58B | 1.53B | 1.31B | 1.26B |
Capital Lease Obligations | 0 | 0 | 28.9M | 43.41M | 36.04M | 62.77M | 54.93M | 43.11M | 47.68M | 196M |
Deferred Tax Liabilities | 1.49M | 721K | 2.09M | 1.66M | 1.49M | 126.01M | 55.87M | 48.81M | 37.76M | 136.86M |
Other Non-Current Liabilities | 86.92M | 71.73M | 35.12M | 19.67M | 26.4M | 102.46M | 74.04M | 49.69M | 32.52M | 62.37M |
Total Liabilities | 298.7M | 321.74M | 315.14M | 261.43M | 264.71M | 2.43B | 2.26B | 2.24B | 1.93B | 1.9B |
Total Debt | 0 | 0 | 36.26M | 52.7M | 45.05M | 1.73B | 1.7B | 1.64B | 1.39B | 1.34B |
Net Debt | -290.07M | -344.78M | -232.41M | -343.4M | -507.78M | 1.53B | 1.45B | 1.33B | 1.08B | 1.05B |
Debt / Equity | - | - | 0.03x | 0.04x | 0.03x | 0.83x | 0.80x | 0.84x | 0.66x | 0.64x |
Debt / EBITDA | - | - | 0.20x | 0.27x | 0.20x | 9.02x | 6.77x | 36.16x | 4.28x | 4.71x |
Net Debt / EBITDA | -5.63x | -3.58x | -1.26x | -1.78x | -2.28x | 7.93x | 5.76x | 29.36x | 3.34x | 3.69x |
Interest Coverage | 26.05x | 278.08x | 209.94x | 56.62x | 144.72x | -0.62x | 0.24x | 0.38x | 1.03x | 2.14x |
Total Equity | 1.2B▲ 0% | 1.26B▲ 5.5% | 1.38B▲ 9.0% | 1.5B▲ 9.1% | 1.62B▲ 7.6% | 2.09B▲ 29.3% | 2.12B▲ 1.6% | 1.97B▼ 7.4% | 2.12B▲ 8.1% | 2.11B▲ 0% |
Equity Growth % | 81.51% | 5.46% | 8.99% | 9.08% | 7.57% | 29.32% | 1.6% | -7.45% | 8.07% | 21.99% |
Book Value per Share | 57.45 | 58.50 | 63.92 | 69.58 | 74.19 | 87.56 | 88.14 | 80.58 | 85.28 | 83.87 |
Total Shareholders' Equity | 1.2B | 1.26B | 1.38B | 1.5B | 1.62B | 2.09B | 2.12B | 1.97B | 2.12B | 2.11B |
Common Stock | 2.02M | 2.05M | 2.07M | 2.11M | 2.13M | 2.4M | 2.41M | 2.45M | 2.47M | 2.52M |
Retained Earnings | 585.62M | 620.75M | 721.78M | 808.65M | 911.79M | 837.5M | 807.85M | 690.16M | 690.89M | 721.02M |
Treasury Stock | 0 | -95K | -157K | -39K | -27K | -243K | -262K | -92K | -22K | -25.18M |
Accumulated OCI | -14.96M | -16.95M | -15.4M | -1.52M | -19.27M | -80.98M | -53.08M | -139.4M | -34.63M | -51.9M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ICUI Cash Flow Statement
ICU Medical, Inc. (ICUI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 154.42M | 160.22M | 101.92M | 222.75M | 267.54M | -62.13M | 166.2M | 204.03M | 179.85M | 167.43M |
Operating CF Margin % | 11.95% | 11.44% | 8.05% | 17.53% | 20.32% | -2.73% | 7.36% | 8.57% | 8.06% | - |
Operating CF Growth % | 71.69% | 3.75% | -36.39% | 118.56% | 20.11% | -123.22% | 367.51% | 22.76% | -11.85% | -2.64% |
Net Income | 68.64M | 28.79M | 101.03M | 86.87M | 103.14M | -74.29M | -29.66M | -117.69M | 732K | 46.34M |
Depreciation & Amortization | 66.57M | 74.73M | 85.21M | 94.85M | 89.7M | 235.15M | 228.79M | 240.86M | 200.74M | 206.47M |
Stock-Based Compensation | 19.35M | 24.24M | 21.92M | 23.95M | 27.34M | 36.02M | 40.56M | 46.88M | 55.76M | 43.71M |
Deferred Taxes | -55.96M | 20.27M | 27.62M | 3.77M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -69K | 37.58M | -22.23M | 30.27M | 32.33M | 44.71M | 62.1M | 36.55M | 12.66M | 16.56M |
Working Capital Changes | 55.89M | -25.41M | -111.64M | -16.97M | 15.04M | -303.73M | -135.6M | -2.57M | -90.04M | -145.65M |
Change in Receivables | -54.53M | -76.74M | -23.68M | 78.05M | 13.76M | -19.15M | 48.63M | -46.84M | 8.88M | -37.71M |
Change in Inventory | 181.7M | -21.77M | -25M | 19.2M | 20.82M | -201.09M | -6.08M | 16.83M | -26.25M | -11.94M |
Change in Payables | 46.65M | 23.27M | -2.7M | -46.41M | 2.35M | 37.47M | -68.3M | 12.53M | 7M | -13.9M |
Cash from Investing | -266.87M | -103.37M | -166.89M | -98.14M | -90.69M | -1.91B | -87.95M | -88.96M | 122.23M | 127.83M |
Capital Expenditures | -79.68M | -100.78M | -106.04M | -100.39M | -68.54M | -90.31M | -83.89M | -79.37M | -88.04M | -86.49M |
CapEx % of Revenue | 6.16% | 7.2% | 8.37% | 7.9% | 5.21% | 3.96% | 3.71% | 3.33% | 3.95% | 4.01% |
Acquisitions | -162.45M | -1.3M | -76.13M | -8.38M | -14.45M | -1.84B | 0 | 0 | 0 | 219.2M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 5.21M | 13.77M | 33K | 14.56M | -12.41M | -8.03M | -8.28M | -10.09M | 210.27M | -4.88M |
Cash from Financing | -44.35M | 8.02M | -10.91M | -40K | -16.87M | 1.64B | -35.98M | -55.8M | -311.52M | -299.31M |
Debt Issued (Net) | -75M | 0 | 0 | -357K | -607K | 1.64B | -30.65M | -52.15M | -308.87M | -266.13M |
Equity Issued (Net) | -4.06M | -6.25M | -10.91M | 317K | 0 | 0 | -5.33M | -1.05M | -2.66M | -2.82M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -4.06M | -6.25M | -18.64M | -12.88M | 0 | 0 | -9.35M | -11.99M | -8.77M | -8.8M |
Other Financing | 34.71M | 14.28M | 0 | 0 | -16.26M | -4.28M | 0 | -2.6M | 0 | -30.35M |
Net Change in Cash | -155.01M▲ 0% | 54.71M▲ 135.3% | -76.11M▼ 239.1% | 127.43M▲ 267.4% | 156.73M▲ 23.0% | -344.04M▼ 319.5% | 45.44M▲ 113.2% | 54.34M▲ 19.6% | -603K▼ 101.1% | -1.37M▲ 0% |
Free Cash Flow | 74.74M▲ 0% | 59.44M▼ 20.5% | -4.12M▼ 106.9% | 122.36M▲ 3068.5% | 186.37M▲ 52.3% | -161.46M▼ 186.6% | 72.53M▲ 144.9% | 124.66M▲ 71.9% | 91.8M▼ 26.4% | 80.4M▲ 0% |
FCF Margin % | 5.78% | 4.25% | -0.33% | 9.63% | 14.16% | -7.08% | 3.21% | 5.23% | 4.12% | 3.73% |
FCF Growth % | 14.3% | -20.48% | -106.94% | 3068.51% | 52.31% | -186.63% | 144.92% | 71.87% | -26.36% | -40.15% |
FCF per Share | 3.58 | 2.75 | -0.19 | 5.67 | 8.56 | -6.76 | 3.01 | 5.11 | 3.69 | 3.19 |
FCF Conversion (FCF/Net Income) | 2.25x | 5.56x | 1.01x | 2.56x | 2.59x | 0.84x | -5.60x | -1.73x | 245.69x | 1.73x |
Interest Paid | 2.05M | 709K | 549K | 1.75M | 858K | 63.71M | 95.91M | 99.72M | 0 | 0 |
Taxes Paid | 5.11M | 12.6M | 9.68M | 31.63M | 19.56M | 27.5M | 35.81M | 25.25M | 0 | 0 |
ICUI Key Ratios
ICU Medical, Inc. (ICUI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 7.39% | 2.34% | 7.65% | 6.03% | 6.61% | -4.01% | -1.41% | -5.76% | 0.04% | 2.19% |
Return on Invested Capital (ROIC) | -2.01% | 1.77% | 7.8% | 6.39% | 8.15% | -1.36% | 0.48% | 0.94% | 2.47% | 1.88% |
Gross Margin | 32.96% | 40.72% | 37.27% | 36.31% | 37.34% | 30.6% | 32.75% | 34.62% | 36.76% | 36.36% |
Net Margin | 5.31% | 2.06% | 7.98% | 6.83% | 7.84% | -3.26% | -1.31% | -4.94% | 0.03% | 2.15% |
Debt / Equity | - | - | 0.03x | 0.04x | 0.03x | 0.83x | 0.80x | 0.84x | 0.66x | 0.64x |
Interest Coverage | 26.05x | 278.08x | 209.94x | 56.62x | 144.72x | -0.62x | 0.24x | 0.38x | 1.03x | 2.14x |
FCF Conversion | 2.25x | 5.56x | 1.01x | 2.56x | 2.59x | 0.84x | -5.60x | -1.73x | 245.69x | 1.73x |
Revenue Growth | 240.72% | 8.31% | -9.56% | 0.38% | 3.56% | 73.21% | -0.92% | 5.44% | -6.38% | -10.89% |
Related:ICUI Dividend History·ICUI Revenue History·ICUI Price History·ICUI P/E History·ICUI Financial Ratios·ICUI Institutional Holders
ICUI SEC Filings & Documents
ICU Medical, Inc. (ICUI) SEC filings — annual & quarterly reports (10-K, 10-Q)
ICUI Frequently Asked Questions
ICU Medical, Inc. (ICUI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ICU Medical, Inc. (ICUI) reported $2.16B in revenue for fiscal year 2025. This represents a 8666% increase from $24.6M in 1996.
ICU Medical, Inc. (ICUI) saw revenue decline by 6.4% over the past year.
Yes, ICU Medical, Inc. (ICUI) is profitable, generating $46.3M in net income for fiscal year 2025 (0.0% net margin).
Dividend & Returns
ICU Medical, Inc. (ICUI) has a return on equity (ROE) of 0.0%. This is below average, suggesting room for improvement.
ICU Medical, Inc. (ICUI) generated $80.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.